Cancer Biological Therapy Market - By Product (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokine), By Route of Administration (Oral, Injectable) & Forecast, 2023-2032
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationCancer Biological Therapy Market - By Product (Monoclonal Antibodies, Vaccines, Cancer Growth Blockers, Blood Cell Growth Factors, Cytokine), By Route of Administration (Oral, Injectable) & Forecast, 2023-2032
Cancer Biological Therapy Market Size
Cancer Biological Therapy Market size was worth more than USD 111.5 billion in 2022 and is expected to record over 7% CAGR from 2023-2032. Rising prevalence of cancer across the globe will accelerate industry expansion.
The growing disease burden and incidences of cancer worldwide will have a significant impact on the cancer biological therapy industry outlook. According to the World Health Organization (WHO), cancer accounted for more than 10 million deaths in 2020. The National Institute of Cancer has further suggested that cancer-related mortality will reach 16.4 million per year by 2040 with 29.5 million new cases annually in the U.S.
Moreover, the fast-paced lifestyles and the higher consumption of highly processed foods, has stirred the substantial increase in alcohol intake resulting in a high prevalence of risk factors, such as obesity and type 2 diabetes. This scenario is therefore emphasizing the need for advanced biological therapies to limit or prevent the growth and spread of tumors.
| Report Attribute | Details |
|---|---|
| Base Year | 2022 |
| Cancer Biological Therapy Market Size in 2022 | USD 111.5 Billion |
| Forecast Period | 2023 to 2032 |
| Forecast Period 2023 to 2032 CAGR | 7% |
| 2032 Value Projection | USD 227 Billion |
| Historical Data for | 2018 to 2022 |
| No. of Pages | 250 |
| Tables, Charts & Figures | 545 |
| Segments covered | Product, Route of Administration, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Side effects of anti-cancer drugs may impede product demand
The rising concerns regarding the potential side effects of anti-cancer drugs and biological therapies could restrict industry progress. Some of the common adversities associated with cancer biological therapies include fever, nausea, inflammation, chronic fatigue, disorientation, and depression, among others. While the impact of these drugs varies from patient to patient, they frequently pose a severe threat to the overall health of a patient, necessitating various treatment methods to overcome added complications, result in high hospital expenditure. Nonetheless, rapid technological advancements in cancer therapies could help provide access to safer alternatives.
Cancer Biological Therapy Market Analysis
Cancer TreatmentA New Hope with Blood Cell Growth Factors The fight against cancer is getting a major boost from blood cell growth factors (BCGFs). By 2032, the market for BCGFs in cancer treatment is expected to soar past a whopping $50 billion. Why the surge? Cancer treatments can take a toll on the body, and BCGFs are coming to the rescue. They help boost patients' immune systems, reducing the risk of infections and side effects like low white blood cell count caused by treatments. This means that patients can stay stronger and keep fighting the cancer more effectively. A particularly serious side effect of cancer treatments is chemotherapy-induced neutropenia, a condition where white blood cell counts drop dangerously low. This affects nearly half of cancer patients worldwide. But BCGFs can help prevent neutropenia, making chemotherapy safer and more effective. With more and more cancer patients using radiation therapy, immunotherapy, stem cell transplants, and other treatments that can lead to neutropenia, the demand for BCGFs is only going to grow. This means a brighter future for cancer patients, with more treatment options and better outcomes.
Cancer biological therapy market size from the oral segment is projected to depict over 6.5% CAGR between 2023-2032. This is attributed to the surging demand for affordable cancer treatments. Oral treatments have a high preference among patients as well as physicians over injectables as they eliminate several unfavorable side effects, such as soreness at the site of injections, and fever or chills.
Oral drugs are easy to administer and do not require doctor’s assistance. The presence of extensive R&D initiatives and clinical trials pertaining to FDA-approved therapeutics will complement the segment development.
Cancer is on the rise in Europe, especially among older people. This is creating a huge demand for new treatments, and biological therapy is one of the most promising options. By 2032, the market for biological therapy in Europe is expected to be worth over $55.5 billion. This is partly due to the fact that cancer rates are increasing, but it's also because the population of Europe is aging. As people get older, they are more likely to develop cancer. Some of the countries with the highest rates of cancer in Europe are Belgium, the Netherlands, Ireland, and Denmark. These countries are also expected to see the biggest demand for biological therapy. In recent years, there has also been an increase in the number of children being diagnosed with cancer in Europe. This is a worrying trend, but it is also creating a need for new and more effective treatments. Biological therapy is a promising option for treating cancer because it targets the specific cells that cause the disease. This makes it more effective than traditional treatments, which often damage healthy cells as well as cancer cells.
Cancer Biological Therapy Market Share
Some leading companies in the cancer biological therapy market include
- AbbVie Inc.
- Amgen Inc.
- Astellas Pharma Inc.
- Bayer AG
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- Merck
- AstraZeneca
- GlaxoSmithKline plc
- ELI Lilly and Company
- Incyte
- Otsuka
- Pfizer
- Sanofi
- F. Hoffmann-La Roche
- Novartis
- Takeda Pharmaceuticals
- Seattle Genetics
- Spectrum Pharmaceuticals
These companies are focusing on product innovations to achieve competitive lead.
Impact of the COVID-19 pandemic
The COVID-19 crisis negatively influenced the cancer biological therapy market with massive disruptions in the cancer care supply chain. It resulted in a radical drop in sales of cancer drugs due to increasing focus on COVID-19 treatment. With surging hospitalization rates worldwide, several healthcare facilities ceased cancer diagnosis and screening services and delayed cancer-related procedures, negatively affecting cancer therapies. However, the post-pandemic era is expected to offer lucrative opportunities for the manufacturers of cancer biological therapies on account of recovery in non-emergency services across healthcare facilities.
The cancer biological therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2018 to 2032, for the following segments
Click here to Buy Section of this Report
By Product
- Monoclonal antibodies (MAB)
- Naked MAB
- Conjugated MAB
- Bispecific MAB
- Vaccines
- Preventive vaccines
- Therapeutic vaccines
- Cancer growth blockers
- Tyrosine kinase inhibitors (TKI)
- Proteasome inhibitors (PI)
- mTOR inhibitors
- Blood cell growth factors (BCGF)
- Lenograstim
- Filgrastim
- Cytokines
- Interferons
- Interleukins
By Route of administration
- Oral
- Injectable
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Poland
- Switzerland
- Netherlands
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Thailand
- Indonesia
- Vietnam
- Latin America
- Brazil
- Argentina
- Mexico
- Chile
- Columbia
- Peru
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Egypt
- Iran
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy